Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Prospective, Randomized, Open Label, Blinded-endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM in Subjects With Mild-to-moderate Essential
Brief Summary: This prospective chronotherapy trial will investigate the potential differing efficacy of ramipril in doses from 5 to 10 mg/day when administered, as a monotherapy either upon awakening from nighttime sleep or at bedtime, to diurnally active patients with grade 1 or 2 essential hypertension, who will be evaluated by 48-hour ABPM before and after pharmacologic intervention. The benefits from this trial may be extremely important, taking into account

1. the high prevalence of non-dipping among patients with essential hypertension
2. the need for a proper 24-hour BP control with particular emphasis on the regulation of nighttime resting BP mean
3. the lacking information on the administration-time dependent effects on BP of ramipril, a widely used ACEI in doses of 5-10 mg/day.


Options:
A: Inclusion Criteria:

- Hypertension defined by a MSSBP \>=150 mmHg (untreated patients) or patients on current anti-hypertensive treatment who remain uncontrolled (i.e. MSSBP \>140 mmHg)

* Randomisation mean 24h blood pressure above 130/80 mmHg
* In addition the patients must fulfill, at least, one of the following criteria:

Controlled type II Diabetes mellitus Hypercholesteremia, currently treated with lipid-lowering drugs Metabolic syndrome MI, CABG or PTCA more than one year ago Stroke or transient ischemic cerebral attack more than one year ago Documented history of peripheral vascular disease, increased IMT, or carotid plaques Documented history of LVH Elderly \>65 years

Exclusion Criteria:

* - MSSBP \>=180 mmHg and/or MSDBP \>= 110 mmHg at any time from Visit 1 to Visit 3
* Inability to discontinue all prior anti-hypertensive medications safely for a period of three weeks
* Mandatory indication for any concomitant medication for coronary artery disease or any other disease that is not allowed during this study.

Other protocol-defined exclusion criteria may apply.
B: Inclusion Criteria:

* as above

Exclusion Criteria:

* patients with a history of ischaemic heart disease, heart failure, cerebrovascular disease, peripheral arterial disease or congenital coronary anomalies, prior to entry into the cohort
* patients with symptoms of chest pain in the 6 months prior to cohort entry
* patients \< 35 or \>100 years of age after eligibility for entry to the cohort
C: Inclusion Criteria:

* Essential hypertension

Exclusion Criteria:

* Severe hypertension.
* Secondary hypertension.
* Grade III/IV hypertensive retinopathy.
* Type 1 diabetes.
* Cerebrovascular or cardiovascular event during the last 12 months prior to inclusion.
* Pregnant or lactating females.
* History of malignancy within the past five years.
* Shift workers.
* Obstructive sleep apnea.
* Use of disallowed concomitant medication.
* Intolerant to ABPM.
D: Inclusion Criteria:

* Male or female subjects ≥18 years of age.
* High-normal BP or essential hypertension.
* Any subject with recommendation for evaluation with ABPM according to the 2007 European Guidelines.
* Informed consent to participate in the study prior to any study procedures.

Exclusion Criteria:

* Known or suspected contraindications to any potential medication under investigation.
* Shift-workers.
* Inability to communicate and comply with all study requirements.
* Persons directly involved in the execution of this protocol.
* Intolerants to the use of the ABPM device.

Answer: C